Ventech

Ventech has been investing in the digital economy from Paris since 1998, which puts it in a strange position relative to most of the funds courting European AI healthcare founders today: it is older than several of them combined. The firm operates across Europe and Asia, and its current attention to health software and data infrastructure reflects a long pattern of following digitization wherever it lands next, rather than a fashionable pivot.

The healthcare thesis sits inside a broader digital economy mandate covering software, marketplaces, and data businesses. Within health, Ventech focuses on digital health platforms and health IT software, with particular interest in the data and infrastructure layers that clinical and administrative workflows increasingly run on. The firm tends to back companies that look like classic software businesses first and healthcare businesses second: recurring revenue, defensible architecture, and a clear path to becoming part of how providers or payers operate. Portfolio detail in healthcare is not disclosed in the source material, so founders should expect Ventech to read more like a generalist software investor with a healthcare appetite than a sector specialist.

Ventech writes Seed, Series A, and Series B checks in the one to five million dollar range, with the flexibility to lead or follow depending on round construction. The firm is headquartered in Paris and invests primarily across Europe, with offices that have historically extended its reach into Germany and Asia. That cross-border footprint matters for healthcare founders thinking about expansion beyond a single national health system, where the regulatory and reimbursement transitions are usually where good companies stumble.

The team consists of partners with backgrounds spanning operating roles, finance, and technology investing. Specific partner names are not provided in the source material, so founders should expect to do their own diligence on which partner leads which sector and how decisions are made.

For founders, Ventech is most useful as a patient, multi-stage software investor with a long memory for what European technology cycles actually look like. The firm is unlikely to win deals on speed or on AI-native pattern recognition, and it is not the right partner for a team that wants a hands-on operational co-builder. It is a good partner for founders who want disciplined capital, the option to take Series A and B from the same fund, and an investor who has watched enough cycles to push back when product narratives drift away from unit economics. Founders should come prepared to discuss data strategy, integration into incumbent health IT environments, and a credible commercial model rather than a research milestone, because that is the territory where Ventech’s questions will be sharpest.